Latest Safety News

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Synertec Corporation has signed a 12-month MOU with global battery leader Ritar International to integrate advanced OPzV battery technology into its Powerhouse microgrid system, aiming to slash costs and scale production rapidly.

Breakthrough Minerals has completed the acquisition of the Errolls Gold Project in Western Australia and raised $1.2 million to fund an upcoming drilling program targeting high-grade gold mineralisation.

HyTerra Limited has successfully completed the Blythe 13-20 well at its Nemaha Project, confirming promising hydrogen and helium presence and expanding its drilling program to three wells.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Cazaly Resources has secured key approvals to commence drilling at the Duke of York prospect within its Goongarrie Gold Project, aiming to validate promising historical gold intercepts and explore new mineralisation along a prolific gold corridor in Western Australia.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Imricor Medical Systems has secured CE Mark approval for its NorthStar Mapping System ahead of schedule, marking a pivotal shift to software-centric MRI-guided cardiac interventions across Europe and the Middle East.

Lefroy Exploration has secured its inaugural toll milling agreement for the Lucky Strike Gold Project, marking a significant step towards production with a February 2026 milling slot at Greenfields Mill.

Clarity Pharmaceuticals reports that its Cu-SARTATE diagnostic agent significantly outperforms the current standard in detecting neuroendocrine tumours, paving the way for a pivotal Phase III study.

Lanthanein Resources is set to raise $2.4 million through a placement and a fully underwritten rights issue, while proposing a strategic name change and share consolidation to streamline its capital structure.